

MUTATED PENICILLIN EXPANDASE AND PROCESS FOR
PREPARING 7-ADCA USING THE SAME

Field of the Invention

The present invention relates to a mutated penicillin expandase
5 having high substrate specificity to penicillin G, recombinant cells
expressing the mutated expandase, and a process of preparing
7-aminodeacetoxycephalosporanic acid (7-ADCA) using the mutated
expandase.

Background of the Invention

10 7-aminodeacetoxycephalosporanic acid (7-ADCA) is one of the
important intermediates for the production of cephalosporins cefalexin,
cefradine, and cefadroxil which are antibiotic compounds commonly and
long used in humans and animals. The industrial process to synthesize
7-ADCA mainly includes two steps: a chemical ring expansion of
15 penicillin G to phenylacetyl-7-ADCA and an enzymatic side chain
cleavage of phenylacetyl-7-ADCA. However, the chemical reaction of
the ring expansion is complex and expensive, and the by-products and the
organic solvents (such as pyridine and HBr) are toxic to the environment.
Therefore, an enzymatic reaction is greatly desirable to replace such
20 chemical reaction.

It has been reported that a natural enzyme, deacetoxycephalosporain
C synthase (DAOCS, or expandase), may be responsible for the catalysis of
the expansion reaction. *Streptomyces* sp. (such as *Streptomyces*
clavuligerus, *Streptomyces ambofaciens* and *Streptomyces chartreusis*) can
25 produce the expandase. As illustrated in EP-A-0341892, the expandase

5

15

25

from a native expandase, resulting in an altered substrate specificity. Several amino acid positions have been mentioned in that patent, and the mutated expandase created by changing one or more of the mentioned amino acids shows a higher activity ratio of penicillin G to penicillin N in a mixture of these two substrates, but has a lower activity on penicillin G and penicillin N individually than wild-type expandase. Therefore, there is still a need to develop a mutated penicillin expandase having more substrate specificity and enzymatic activity on penicillin G.

Summary of the Invention

The present invention provides mutated expandase having expansion activities 2 to 32 folds higher on penicillin G than wild-type expandase.

One object of the invention is to provide a mutated penicillin expandase which comprises an amino acid substitution at one or more residue positions corresponding to those of a wild-type expandase selected from the group consisting of methionine 73, serine 79, valine 275, leucine 277, cysteine 281, glycine 300, asparagine 304 and isoleucine 305, provided that the amino acid substitution at the residue position of asparagine 304 is not N304L. In particular, the invention provides a mutated penicillin expandase which comprises one or more specific amino acid substitutions selected from the group consisting of M73T, S79E, V275I, L277K, C281Y, G300V, N304K, I305L and I305M, wherein the residue positions of the amino acid substitution correspond to those of a wild-type expandase.

Another object of the invention is to provide an isolated nucleic acid molecule encoding the mutated penicillin expandase.

Another object of the invention is to provide a recombinant vector comprising the nucleic acid molecule of the invention and a regulatory sequence operatively linked thereto.

5 Still another object of the invention is to provide recombinant cells comprising the nucleic acid molecule of the invention.

In another aspect, the invention provides a method to produce a mutated penicillin expandase. In one embodiment of the invention, the method comprises expressing the nucleic acid molecule of the invention and recovering the mutated penicillin expandase. In another embodiment
10 of the invention, the method comprises culturing the recombinant cells of the invention to express the mutated penicillin expandase and recovering the mutated penicillin expandase from the cell culture.

In another aspect, the invention provides a process for producing 7-ADCA comprising treating penicillin G with the mutated penicillin
15 expandase of the invention to produce phenylacetyl-7-ADCA, followed by deacylating the phenylacetyl-7-ADCA to produce the 7-ADCA.

In still another aspect, the invention provides a process for producing 7-ADCA, which process comprises the steps of (a) cultivating penicillin G producing cells which is transformed with the nucleic acid molecule of the
20 invention under conditions suitable for production of penicillin G and expression of the mutated penicillin expandase such that the penicillin G is expanded by the mutated expandase and phenylacetyl-7-ADCA is produced; (b) deacylating the phenylacetyl-7-ADCA to produce the 7-ADCA.

The present invention will be fully understood from the detailed description and figures as given below.

Brief Description of the Drawings

FIG. 1 shows the SDS-PAGE results of the purified DAOCS of the invention. Lanes 1 to 9 represent molecular weight markers and the purified DAOCS of YS5, YS8, YS11, YS12, YS16, YS49, YS53 and YS59 mutants, respectively. Each loaded DAOCS dose was in an amount of 5 μ g.

FIG. 2 shows the SDS-PAGE results of the purified DAOCS of the invention. Lanes 1 and 2 represent molecular weight markers and the purified DAOCS of YS67 mutant, respectively. The loaded DAOCS dose was in an amount of 5 μ g.

FIG. 3 shows the SDS-PAGE results of the purified DAOCS of the invention. Lanes 1 represents molecular weight markers. Lanes 2 to 5 represent samples irrelevant to the invention. Lanes 6 and 7 represent the purified DAOCS of SC29 and SC39 mutants, respectively. The loaded DAOCS dose was in an amount of 5 μ g.

FIG. 4 shows the SDS-PAGE results of the purified DAOCS of the invention. Lanes 1 represents molecular weight markers. Lanes 2 to 5 represent samples irrelevant to the invention. Lanes 6 to 9 represent the purified DAOCS of YS 98, YS108, YS115 and YS125, respectively. The loaded DAOCS dose was in an amount of 5 μ g.

Detailed Description of the Invention

The primary aspect of the present is to provide a mutated penicillin expandase having a better substrate specificity to penicillin G, wherein the mutated penicillin expandase comprises an amino acid substitution at one or more residual positions corresponding to those in a wild-type expandase selected from the group consisting of methionine 73, serine 79, valine 275, leucine 277, cysteine 281, glycine 300, asparagine 304 and isoleucine 305, provided that the amino acid substitution at the residue position of asparagine 304 is not N304L. More specifically, the invention provides a mutated penicillin expandase comprising one or more amino acid substitutions selected from the group consisting of M73T, S79E, V275I, L277K, C281Y, G300V, N304K, I305L and I305M.

A "wild type penicillin expandase", as used herein, refers to the native penicillin expandase obtained from *Streptomyces sp.* Preferably, the wild-type expandase is obtained from *Streptomyces clavuligerus*. The native penicillin expandase and its corresponding gene (*cefE* gene) have been well characterized and described in the prior art (e.g., EP-A-0366354 and EP-A-0341892). Persons skilled in the art can readily obtain the nucleic acid sequences of the wild-type penicillin expandase and the corresponding amino acid sequences from the prior art.

The mutated penicillin expandase of the invention comprises the functional equivalents of the same. As used herein, the "functional equivalents" of the mutated penicillin expandase may contain further amino acid mutations (e.g., deletions, additions or substitutions) located at positions other than those described above, wherein said further amino acid

mutations result in silent changes and thus do not substantially affect the function (e.g., enzyme activity) of the mutated penicillin expandase. Furthermore, in the "functional equivalents" of the mutated penicillin expandase, the specific amino acid substitutions (i.e., selected from M73T, S79E, V275I, L277K, C281Y, G300V, N304K, I305L and I305M) may be
5 exchanged with other amino acid substitutions of similar characteristics which result in a silent change. For example, a mutated penicillin expandase with an amino acid substitution of "S79D" is functional equivalent to that with an amino acid substitution of "S79E," since the
10 amino acid D (aspartic acid) and E (glutamic acid) are both classified as acid amino acids and are of similar characteristics.

In another aspect, the invention provides an isolated nucleic acid molecule encoding the mutated penicillin expandase of the invention. The isolated nucleic acid molecule of the invention is obtained by mutating
15 the nucleic acid encoding the wild-type penicillin expandase. A conventional mutation-inducing technical is well known in the art, such as irradiation of with gamma rays or ultraviolet light or treatment with a mutagen, such as hydroxylamine and ethylmethane, or site-directed mutagenesis. Persons skilled in the art can choose a suitable mutagenesis
20 technology to obtain a mutated nucleic acid molecule. The mutated nucleic acid molecules can be further cloned and selected for their biological activities. More detailed technologies, comprising mutagenesis, cloning and screening for biological activities, used to obtain the isolated nucleic acid molecules of the invention are described in the following
25 examples.

According to the invention, the isolated nucleic acid may be inserted

into a vector to form a recombinant vector. The term "vector" used herein means a nucleic acid molecule, which is capable of carrying and transferring a nucleic acid segment of interest into a host cell for the purpose of expression or replication of the same. In particular, a vector refers to a plasmid, cosmid, bacteriophage or virus. Typically, the nucleic acid segment of interest is operatively linked to a regulatory sequence such that, when introducing into a host cell, for instance, the nucleic acid segment can be expressed in the host cell under the control of the regulatory sequence. The regulatory sequence may comprise, for example, a promoter sequence (e.g., cytomegalovirus (CMV) promoter, simian virus 40 (SV40) early promoter and T7 promoter), replication origin and other control sequences (e.g., Shine-Dalgarno sequences and termination sequences). Preferably, the nucleic acid segment of interest may be connected to another nucleic acid fragment such that a fused polypeptide (e.g., His-tag fused polypeptide) is produced and beneficial to the subsequent purification procedures. The method for identifying and selecting the regulatory sequences are well known to the skilled persons and widely described in the literatures. The skilled persons can readily construct the recombinant vector of the invention according to the specification and the well-known technologies.

The recombinant vector of the invention can be introduced into host cells to produce the mutated penicillin expandase. Accordingly, recombinant cells transformed with the recombinant vector is within the scope of the invention. Such recombinant cells can be prokaryotic (e.g., bacteria) or eukaryotic (e.g., fungi, animal and plant cells). In particular, the recombinant cells of the invention are penicillin G producing cells,

preferably *Penicillium chrysogenum* cells, which can be used to produce 7-ADCA *in vivo*, as described below. A number of transformation technologies, such as a calcium chloride treatment, Calcium-PEG procedure, electroporation, DEAE-dextrin-mediated transfection, lipofection and microinjection are well described in many literatures. The skilled persons can choose a proper technology depending on the nature of the host cells and the vector to be introduced in the host cells.

A method for producing the mutated penicillin expandase is also provided in the invention. The recombinant cells described above can be cultured in a suitable condition to express the mutated penicillin expandase and then the expressed expandase is recovered and purified. Those skilled in this art will appreciate that the recovering and purifying method is widely described in many references and is not limited, for example, by various chromatographies (e.g., HPLC or affinity columns).

The genetic engineering methods mentioned above such as DNA mutagenesis, cloning, vector construction, transformation, protein expression, and purification can be accomplished by those skilled in this art, and which can be seen, for example, in *Molecular Cloning: A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds. (1989).

The present invention is also related to a process to produce 7-ADCA, which process comprises the steps of treating penicillin G with the mutated penicillin expandase of the invention to produce phenylacetyl-7-ADCA and deacylating the phenylacetyl-7-ADCA to produce the 7-ADCA. In particular, the mutated expandase is expressed

and recovered as stated above, and then added with the substrate penicillin G. The mixture is incubated under conditions (e.g., at a temperature of 30 °C) suitable for the enzyme activity of the mutated expandase such that a ring expansion reaction is conducted by the mutated expandase and the substrate penicillin G is converted to phenylacetyl-7-ADCA. Preferably, phenylacetyl-7-ADCA is purified through a simple solvent extraction, for example, and then treated with a suitable enzyme (e.g., penicillin amidase, as described in EP-A-0453047) such that the phenylacetyl side chain is removed and the desired 7-ADCA is obtained. In another aspect, the substrate penicillin G can be directly added into the cell culture of the recombinant cells expressing the mutated expandase of the invention. The expressed expandase then reacts with the penicillin G and converts it into phenylacetyl-7-ADCA, followed by deacylation of the phenylacetyl-7-ADCA to produce the desired 7-ADCA.

It has been found that penicillin G producing cells (e.g., *Penicillium chrysogenum*) transformed with an expandase-encoding gene is capable of producing phenylacetyl-7-ADCA *in vivo*. Accordingly, another aspect of the invention is to provide a process to produce 7-ADCA using penicillin G producing cells, which process comprises the steps of (a) cultivating penicillin G producing cells which is transformed with the recombinant vector of the invention under conditions suitable for production of penicillin G and expression of the mutated expandase of the invention such that the penicillin G is expanded by the mutated expandase and phenylacetyl-7-ADCA is produced; (b) deacylating the phenylacetyl-7-ADCA to produce the 7-ADCA. The term "penicillin G producing cells" used herein refers to cells capable of naturally producing

penicillin G in a normal condition without any genetic engineering technologies (e.g., transformation). Preferably, the penicillin G producing cells are cells of *Penicillium chrysogenum*. The phenylacetyl-7-ADCA produced from Step (a) can be optionally purified by filtration and extraction steps. The detailed procedures, such as transformation and fermentation of such cells and purification of the produced phenylacetyl-7-ADCA, have been described in the prior art, such as US 5,919,680 and EP 5,731,165 which are incorporated herein for reference.

Examples

The present invention will become apparent with reference to the examples below. The examples described below are given by way of illustration only and are not intended to be any limitation of the present invention.

Materials

All chemicals were purchased from Merck unless stated otherwise. Strain *Streptomyces clavuligerus* was ordered from Culture Collection & Research Center (Taiwan). Oligonucleotides were synthesized by Genset (Singapore Biotech). DNA sequences were analyzed by Mission Biotech (Taiwan). Liquid chromatography- Mass analysis was performed by Protech Laboratory (Taiwan). Penicillin G was from Harbin Pharmaceutical Co. (China). C¹⁴-penicillin G was ordered from Moravek. Penicillin N, deacetoxycephalosporin C, and cephalosporin G were synthesized in this laboratory. Other materials and supplied companies are indicated as follow: enzymes for DNA manipulation (Promega); Zero Blunt TOPO PCR cloning kit (Invitrogen); DNA gel extraction kit, GFX

Micro Plasmid Prep kit, & FPLC apparatus and columns (Amersham Pharmacia Biotech Inc.); PCR clean up-M (Viogene); pET24a, pET30a, BL21(DE3), and Tuner cells (Novagen); Bradford reagent, 30% acrylamide/bis-acrylamide solution, and PAGE apparatus (Bio-Rad);
5 HPLC set (LC-10AT, Sil-10AD, SPD-10A; Shimadzu); C₁₈ column (250 x 4.6 mm, 5 μ ; Hypersil); HPLC data analysis software (Scientific Information Service Corporation); pefabloc SC, and leupeptin (Roche)

Example 1 Random Mutagenesis

The *cefE* gene fragment was cut off from pYB4, a pET24a backbone
10 with a BamHI-Hind III *cefE* insert cloned from *Streptomyces clavuligerus* using Zero Blunt TOPO PCR Cloning kit, treated with 0.8 M hydroxylamine at 65°C for 2 hours, cleaned up with PCR Clean up-M kit, then ligated back into the backbone vector. This mutated *cefE* pool was transformed into BL21(DE3) by electroporation, and transformants were
15 selected on LB plates with 50 μ g/ml of kanamycin. The mutated transformants were subjected for an activity improvement screening.

Example 2 Activity Improvement Screening

The mutated transformants were grown in a 96-well plate containing 56.7 μ l of LB medium with kanamycin in each well. Then 0.1 mM IPTG
20 was added into each well to induce DAOCS indirectly at 30°C for 2 hours of shaking, followed by another 1 hour of shaking after an addition of 7 μ l of 100 mg/ml lysozyme. The activity of DAOCS was measured by an addition of 30 μ l of assay mixture (500 mM Mops/pH 7.0, 18 mM FeSO₄, 40 mM ascorbate, 25.6 mM α -ketoglutarate and suitable amount of
25 penicillin G), and incubated at 30°C for another 1 hour of shaking. The

resulting mixture was loaded on an 8 mm thick paper disc, and placed onto a bioassay plate seeded with *Escherichia coli* ESS strain (a β -lactam supersensitive mutant, a gift from Dr. Demain) as described in Cho H. et al., *Proc. Natl. Acad. Sci. USA*, 95: 11544-11548 (1988). The transformants
5 with clear zone bigger than that of unmutated control strain were selected and subjected for further activity confirmation by TLC. After the activity improvement screening, the mutated *cefE* was manipulated into a NdeI-Hind III insertion version in the same vector (pET24a), and the mutants such as YS5 (V275I), YS53 (C281Y) and YS59 (S79E) were
10 selected.

A TLC method to separate penicillin G and cephalosporin G was also developed for bioassay screening. Silica plates 60 F254 were used as a solid phase and the mobile phase was a mixture of chloroform: acetone: acetic acid = 6: 5: 0.5 (volume ratio). C¹⁴ labeled penicillin G was used in
15 the standard assay with 20 μ g of cell extract (quantitated with Bio-Rad Bradford kit using BSA as a standard), and after addition of ethanol the mixture was applied directly onto TLC plate without centrifugation.

Example 3 Site-Directed Mutagenesis

The wild-type expandase gene (i.e., *cefE*) was PCR cloned from
20 *Streptomyces clavuligerus* and inserted into pET30a NdeI-Hind III site, and the resulted plasmid was designated as pYS16. The Quick Change Mutagenesis Kit was used to produce site-directed mutants of pYS16. The mutated sites were chosen based on the crystal structure of DAOCS (Valegard K. et al., *Nature*, 394: 805-809 (1998)) using Swiss-Pdb Viewer
25 (V3.7b2) program by selecting residuals surrounding active center within

10 Å. Each site was changed to Ala residual first, then a positive charge residual, a hydrophobic residual and a sulfur-containing residual. The primers were designed according to the manufacturer's manual. The resulted mutants were confirmed by DNA sequencing the harbored plasmids, and the cell crude extracts were prepared and subjected for DAOCS activity assay.

Example 4 DAOCS Activity Assays

BL21(DE3) transformants were grown overnight in 5 ml of LB medium with 50 μ g/ml kanamycin at 30°C. This culture was used to inoculate 100 ml of the same medium and grown at 30°C for 1 hour. Then 0.1 mM IPTG was added to induce DAOCS indirectly at 30°C for 4 hours. Cells were harvested, washed with buffer A (50 mM Mops/pH 7.5, 1 mM PMSF, 1 mM DTT, and 0.5 μ g/ml leupeptin), lysed by sonication (VCX 750; Sonics & Materials, USA), and centrifuged at 15,000 xg for 15 minutes. The supernatant was used as a cell extract.

For penicillin G, 20 μ l of cell extracts was added into a standard 200 μ l assay reaction containing 50 mM Mops/pH 7.5, 4 mM ascorbate, 1 mM FeSO₄, 4 mM α -ketoglutarate and 7 mM penicillin G, and incubated at 30°C for 20 minutes. The reaction was stopped by addition of 200 μ l of ethanol, followed by a centrifugation at 15,000 xg for 5 minutes. The concentration of cephalosporin G in supernatant was analyzed by HPLC with 40 μ l injection. The mobile phase was 25 mM potassium phosphate/pH 6.5 with 19 % acetonitrile at a flow rate of 1 ml/min. The retention time for cephalosporin G was 8.5 minutes and 12.5 minutes for penicillin G with detection at 215 nm, and the product at 8.5 minutes in

DAOCS reaction was confirmed by LC-MS to have a molecular weight of 370. The site-directed mutants such as YS49 (L277K), YS8 (I305L), YS11 (I305M), and Y12 (N304K) having higher expandase activities on penicillin G than the parent strain YS16 were obtained. The different combinations of the mutated amino acids mentioned above were also constructed by site-directed mutagenesis.

Example 5 DAOCS Purification

The cell extract (2 ml) of a candidate mutant was applied onto a HiTrap Q column (5 ml) equilibrated with buffer B (50 mM Mops/pH 7.5, 1 mM DTT, 0.4 mM pepabloc SC, and 0.5 μ g/ml leupeptin). Then, the column was washed with 20 ml of buffer B, followed by a further wash with 25 ml of 120 mM NaCl in buffer B, and DAOCS was eluted off with 20 ml of 150 mM NaCl in buffer B. The DAOCS containing fractions were pooled (10 ml), concentrated by UF 15 device (NMWL 5K; Millipore), and loaded onto a Hiload Superdex 75 (16/60) column pre-equilibrated with buffer B at a flow rate at 1 ml/min. The DAOCS thus purified had a purity more than 90% as judged by SDS-PAGE, see Figs. 1 and 2, and was stored in 1 mM DTT and 2 mg/ml BSA at -80°C immediately.

Example 6 Kinetic Assays of Purified DAOCS

The standard penicillin G assay was followed for Kinetic assay, but 20 μ g of purified DAOCS was used and the concentration of α -ketoglutarate was reduced to 1 mM. Kinetic parameters were obtained from triplicate experiments by Hanes-Woolf Plot. For assays using penicillin N as main substrate, a total volume of 240 μ l reaction containing 50 mM Hepes/pH 7.5, 0.4 mM ascorbate, 0.1 mM FeSO₄, 0.1

mM α -ketoglutarate, 0.1 mM penicillin N and 0.5 μ g of purified DAOCS was incubated at 30°C for 10 minutes, then the same volume of 10 mM EDTA/pH 7.5 was added, and the mixture was subjected to ultrafiltration with UF 0.5 device (NMWL 5000, Millipore). The filtrate was analyzed
 5 by HPLC using 25 mM potassium phosphate /pH 6.5 as a mobile phase. The retention time of DAOC and penicillin N was 12 minutes and 13.5 minutes, respectively. The results of kinetic parameters are shown in Table 1, wherein the definition and calculation of the parameters are described in Lehninger et al. *Principles of Biochemistry*, 2.sup.nd Ed.
 10 Worth Publishers, New York (1993) which is incorporated herein for reference.

Table 1: Kinetic parameters for penicillin N and penicillin G

Strains	K_m (mM)	k_{cat} (S^{-1})	k_{cat} / K_m ($M^{-1}S^{-1}$)
<u>For penicillin N:</u>			
YS16 (wild-type)	0.014 ± 0.006	0.307 ± 0.038	22,000
YS5(V275I)	0.012 ± 0.003	0.252 ± 0.020	20,000
YS8(I305L)	0.006 ± 0.002	0.284 ± 0.030	44,000
YS11(I305M)	0.012 ± 0.001	0.310 ± 0.004	26,000
YS12 (N304K)	0.004 ± 0.001	0.366 ± 0.023	92,000
YS125(N304L)	0.018 ± 0.004	0.415 ± 0.063	23,000
YS49(L277K)	0.011 ± 0.005	0.220 ± 0.042	20,000
YS53(C281Y)	0.006 ± 0.001	0.273 ± 0.014	47,000

YS59(S79E)	0.009± 0.003	0.178± 0.019	20,000
YS115(M73T)	0.006± 0.003	0.239± 0.009	40,000
YS67(V275I & I305M)	0.013± 0.005	0.316± 0.032	24,000

For penicillin G:

YS16 (wild-type)	2.58± 0.22	0.0302± 0.0007	12
YS5(V275I)	1.68± 0.20	0.0335± 0.0008	20
YS8(I305L)	0.66± 0.07	0.0506± 0.0010	77
YS11(I305M)	0.75± 0.04	0.0968± 0.0013	129
YS12 (N304K)	0.22± 0.03	0.0376± 0.0002	171
YS125(N304L)	0.55± 0.12	0.0268± 0.0004	49
YS49(L277K)	0.72± 0.02	0.0343± 0.0005	48
YS53(C281Y)	0.68± 0.34	0.0496± 0.0022	73
YS59(S79E)	0.75± 0.02	0.0210± 0.0002	28
YS115(M73T)	0.74± 0.16	0.0418± 0.0014	56
YS67(V275I & I305M)	0.25± 0.08	0.0972± 0.025	389

As shown in Table 1, all mutants have expansion activities 2 to 32 folds higher on penicillin G than wild-type expandase as implicated in k_{cat}/K_m ($M^{-1}S^{-1}$) parameters. In contrast, these mutants do not cause significant changes in kinetic parameters obtained with penicillin N, except for mutant YS12 which has expansion activities 4 folds higher than

wild-type YS16. Making a comparison between YS12 (N304K) of the invention and YS125 (N304L) as disclosed in Chih H. S. et al *supra*, YS125 has the expansion activity 4 folds higher on penicillin G than wild-type expandase, and YS12 has the expansion activity 14 folds higher on penicillin G than wild-type expandase.

The relative activities of the mutants are determined according to Chih H. S. et al *supra* with the activity of wild-type DAOCS as 100% and shown in Table 2. The assay was performed with 1 mM penicillin G, and the other conditions were the same as standard assay.

Table 2: The relative activities of purified combined mutants compared to wild type

DAOCS

Strains	Mutated sites	Relative Activities (%)
YS16	---	100
YS67	275I, 305M	500
YS74	275I, 304K, 305L	300
YS81	275I, 281Y, 305M	1290
YS88	79E, 275I, 281Y	430
YS94	281Y, 304K, 305M	650
YS96	79E, 275I, 305M	1110
YS100	79E, 275I, 305L	470
YS76	79E, 275I, 281Y, 305L	250
YS108	300V	410

SC29	275I, 281Y, 300V	620
SC39	73T, 281Y	610